**Abstract**

Muscarinic M~1~ receptor (CHRM1) positive allosteric modulators represent a promising approach to treating the cognitive deficits of schizophrenia. Hence, we decided to extend studies using cloned receptors and animal models to study CHRM1 ortho- and allosteric binding in human cortex. Therefore, we measured the displacement of \[^3^H\]NMS(0.13nM) with acetylcholine(0---1mM) in the presence of BQCA (positive allosteric modulator: 0---3µM) using tissue from muscarinic receptor deficit schizophrenia (MRDS) subjects (defined by a marked loss in \[^3^H\]pirenzepine binding to cortical CHRM1 (\~75)), other schizophrenia subjects, and non-psychiatric control subjects. This is a measure of the response of CHRM1 to positive allosteric modulation. CHRM binding sites have been shown to be ion dependent and hence we repeated our experiments using cortex from subjects without a psychiatric illness and \[^3^H\]NMS (0.13nM) or \[^3^H\]pirenzepine (7nM) in the presence or absence of Zn^2+^ (10mg/ml) and Mg^2+^ (10mg/ml). As with cloned CHRM1, BQCA increases the affinity of the CHRM1 orthosteric site for acetylcholine in human cortex (logIC~50~: 0µM BQCA=−4.95, 0.3μM BQCA=−5.50, and 3.0μM BQCA=−6.21). The effect of BQCA was reduced in MRDS subjects (p\<0.01; Cohen's d=−0.948), but not of sufficient magnitude to suggest allosteric modulators will not elicit a response in MRDS subjects. Zn^2+^ reduced specific \[^3^H\]pirenzepine (p=0.025 cohen's d=−1.625) and \[^3^H\]NMS (p=0.0003 cohen's d=−5.54) binding; Mg^2+^ and Zn^2+^ enhanced acetylcholine displacement of \[^3^H\]NMS binding (logIC~50~: 0mg/ml Mg^2+^ or Zn^2+^=−4.091; 10mg/ml Mg^2+^=−4.436; 10mg/ml Zn^2+^=−7.294), but Mg^2+^ reduced and Zn^2+^ enhanced displacement of \[^3^H\]pirenzepine binding (logIC~50~: 0mg/ml Mg^2+^ or Zn^2+^=−4.656; 10mg/ml Mg^2+^=−4.380; 10mg/ml Zn^2+^=−5.029). Additionally, both Mg^2+^ and Zn^2+^ enhanced the effect of BQCA on \[^3^H\]NMS (∆logIC50: 0mg/ml Mg^2+^ or Zn^2+^=−0.193; 10mg/ml Mg^2+^=−1.082; 10mg/ml Zn^2+^=−1.694), but not \[^3^H\]pirenzepine (∆logIC50: 0mg/ml Mg^2+^ or Zn^2+^=−0.227; 10mg/ml Mg^2+^=−0.256; 10mg/ml Zn^2+^=−0.229), binding. Our data suggests that both orthosteric and allosteric sites of CHRMs have complex and differing responses to divalent cations.
